CEMIP and neoplasm: Mechanistic studies in hepatocellular and colorectal cancer cells have shown that CEMIP knockdown leads to decreased levels of cyclin D1 and E1, hindering cell-cycle progression, increasing apoptosis, and attenuating tumor growth and metastasis [40,70].